Nanomedicine is playing a growing part in pharmaceutical research and development (R&D), primarily in the form of nanoparticle-based delivery systems for drugs and imaging agents. Indeed, by some quantitative measures, the field is flourishing; over the past decade there has been an explosive growth in associated publications, patents, clinical trials and industry activity. For example, a search of the worldwide patent literature using 'nanoparticle and drug' resulted in over 30,000 hits, perusal of the ClinicalTrials.gov website using the term 'nanoparticle' found more than 100 current studies, and Nanowerk -a leading nanotechnology website -currently lists 356 companies with interests in nanobiotechnology or nanomedicine.
Amidst this enthusiasm, however, a few notes of concern are beginning to be heard. For example, an article provocatively entitled "Cancer nanomedicines: So many papers and so few drugs!" describes the difficult path for the clinical development of nanoparticle-based drugs 1 . Similarly, a recent overview of nanomedicine cautions against 'overpromising' the benefits of this technology: "Every month, articles claim novel/superior designer nanosized therapeutics, imaging agents, theranostics, and also nanomaterials to promote tissue repair. Most are, as yet, far from first in patient clinical trials, and many will never arrive there" 2 . New biomedical technologies have often undergone a similar life cycle. Initially, exciting pioneering studies result in a huge surge of enthusiasm in academia and in the commercial arena. Then, some of the problems and limitations inherent in the technology emerge, the initial enthusiasm is deflated, and many players leave the field. A few enthusiasts persist and eventually the technology finds its appropriate place in research as well as in clinical and commercial applications. It seems possible that nanomedicine is now verging on the phase of disillusionment.
One facet of the field where this may be becoming apparent is its funding. As much of the academic research on nanomedicine in the United States has been funded by the US National Institutes of Health (NIH), it is interesting to look at trends in NIH funding for this area. In the early 2000s, the NIH leadership recognized the growing importance of nanomedicine and initiated several major initiatives. In addition to traditional individual investigator (R01) type grants, various large-scale research programmes were established. This includes the US National Cancer Institute's Alliance for Nanotechnology in Cancer, which has invested over US$150 million primarily in large centres of research excellence. Similarly, the US National Heart, Lung and Blood Institute's Program of Excellence in Nanotechnology (PEN) also supports several large research centres. Starting in 2005, the NIH Director's Office funded eight nanomedicine development centres that addressed basic research issues in the field. All of these thrusts involved funding levels far in excess of R01 grants and utilized monies that were sequestered for these specific projects.
However, the NIH funding landscape for nanomedicine may be changing. The Director's Office is no longer accepting applications in the nanomedicine area, and the future of the Alliance and PEN programmes will be decided over the next year or so. Currently, all new submissions for nanomedicine grants must go through traditional NIH mechanisms where there is no sequestration of funds, and nanomedicine proposals must therefore compete with proposals in other areas of research. So, although overall NIH support for nanomedicine remains solid, with over $300 million in funding (according to NIHRePORTER), other priorities such as the human microbiome, global health and undiagnosed diseases are currently receiving targeted funding, whereas nanomedicine is not.
If there is a loss of enthusiasm for nanomedicine, especially as represented by nanoparticle-mediated drug delivery, this may be due to a growing understanding of some of the constraints inherent in the technology. First, restricted biodistribution implies treatment limitations. Drug-bearing nanoparticles are usually given by injection into the bloodstream and must cross the layer of endothelial cells that line blood vessels before encountering tissue cells. Typical 50-100 nm nanoparticles are far too large to cross the endothelial barrier in healthy tissues, except in the liver and spleen where there are gaps or fenestrations between the endothelial cells. In some cancers, the rapid growth of intratumoural blood vessels also results in endothelial gaps that allow nanoparticle delivery. However, it is clear that this effect does not occur in all cancers and that there are many barriers to nanoparticle penetration into tumours 3 . Obviously, it is important to be able to treat diseases based in a variety of tissues and not just in the liver, spleen and a few select tumour types. At present, this cannot reliably be accomplished with nanoparticles.
Second, nanoparticle drugs present many challenges in terms of pharmaceutical development. The drugnanoparticle moiety is far more complicated than the parent drug alone and thus formulation and production scale-up may be difficult and costly. Early nanodrugs were distributed into the body passively, essentially in a manner that reflected their physical characteristics such as size and surface properties, but newer nanomedicines under development often include a 'targeting' moiety that is designed to promote the association of the nanoparticle with a particular cell type or tissue. There are clearly substantial additional technical challenges for such targeted nanomedicines, as noted in an excellent recent review 4 that discusses their advantages and limitations; for example, the addition of a targeting ligand may compromise the desirable ability of the nanoparticle to have a long lifetime in the circulation.
Addressing these challenges would be strongly justified if major benefits were to accrue to patients. But is this happening? Although we do not know the potential benefits of the nanomedicines currently under development, we can examine the early-generation nanoparticle drugs that entered the clinic in the 1990s and 2000s, such as the liposomal agents Doxil and Ambisome and the protein-drug nanocomplex Abraxane. These agents are far more costly than their parent drugs (doxorubicin, amphotericin B and paclitaxel, respectively). Furthermore, these nanomedicines made their mark in the clinic primarily by reducing toxicity rather than improving efficacy. Although reduced toxicity can certainly improve the quality of life for patients, a relatively high cost coupled with minimal improvements in effectiveness may become an issue for nanomedicines. Given that the next generation of targeted nanomedicines are likely to be extraordinarily costly, it will be crucial for them to provide improved therapeutic outcomes, such as extension of life in patients with cancer, as well as reduced toxicity, as both national and private health-care reimbursement organizations are increasingly using rigorous economic standards such as cost per quality-adjusted life year. Indeed, reflecting this issue, a recent small-scale clinical trial indicating that Abraxane demonstrated no advantage over paclitaxel as a first-line therapy for metastatic breast cancer 5 caused a considerable stir as some US payers reconsidered their reimbursement policies on Abraxane.
Nanomedicine will continue to evolve and will no doubt eventually find an important place in health care. Nonetheless, at present it seems prudent to view the field with a critical eye, to be aware of its limitations as well as its capabilities and to avoid overselling its promise.
